Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Cabazitaxel in platinum pre-treated patients with locally advanced or metastatic transitional cell carcinoma who developed disease progression after platinum based chemotherapy : results of the phase II CAB-B1 trial

Tools
- Tools
+ Tools

Zarkar, A., Marshall, Andrea, Davies, A., Ford, D., James, N. D. and Dunn, Janet A. (2019) Cabazitaxel in platinum pre-treated patients with locally advanced or metastatic transitional cell carcinoma who developed disease progression after platinum based chemotherapy : results of the phase II CAB-B1 trial. International Journal of Cancer Research & Therapy, 4 (4).

[img]
Preview
PDF
WRAP-cabazitaxel-in-platinum-pre-treated-patients-with-locally-advanced-or-metastatic-transitional-cell-carcinoma-Dunn-2019.pdf - Published Version - Requires a PDF viewer.
Available under License Creative Commons Attribution 4.0.

Download (354Kb) | Preview
Official URL: https://www.opastonline.com/international-journal-...

Request Changes to record.

Abstract

There is a paucity of chemotherapy options for patients with urothelial cancers who have relapsed following platinum based chemotherapy (CT).
CAB-B1 was a single centre phase II randomised controlled trial of Cabazitaxel (CAB; 25mg/m2 q3 week for 6 cycles) versus
best supportive care (BSC) in patients with histologically proven transitional cell carcinoma (TCC), locally advanced or
metastatic, who had recurred after receiving platinum based treatment. Primary outcome was overall response rate (ORR)
using RESIST. Secondary outcomes included Progression Free Survival (PFS) and Overall Survival (OS).
Between January 2013 and October 2016, 20 patients were randomised (10 on each arm). BSC included paclitaxel CT for 9
patients and radiotherapy for 1 patient. 8 patients completed 6 cycles of CT (3 on CAB; 5 on BSC). 2 patients had an ORR
on CAB and 1 patient on BSC. Median OS was 5.8 months (95% confidence interval (CI) 0.7-14.6) for CAB patients and
7.5 months (95% CI 1.0-10.8) for BSC patients. Median PFS was 4.8 months (95% CI 0.7-8.3) for CAB patients and 3.7
months (95% CI 1.0-7.0) for BSC patients.
CAB-B1 successfully reached the efficacy target for 1st stage, showing that there could be a role for CAB in these patients.

Item Type: Journal Article
Subjects: R Medicine > RC Internal medicine
R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculty of Medicine > Warwick Medical School > Health Sciences > Clinical Trials Unit
Faculty of Medicine > Warwick Medical School > Health Sciences
Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Bladder -- Cancer, Bladder -- Cancer -- Treatment, Cancer -- Chemotherapy
Journal or Publication Title: International Journal of Cancer Research & Therapy
Publisher: Opast Publishing Group
ISSN: 2476-2377
Official Date: 5 November 2019
Dates:
DateEvent
5 November 2019Published
30 October 2019Accepted
Volume: 4
Number: 4
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access
Related URLs:
  • Publisher
  • Publisher
  • https://opastonline.com/wp-content/uploa...

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us